Filing Flows › Taysha Gene Therapies (TSHA) › Recalls, complaints & regulation

Taysha Gene Therapies (TSHA): clinical trials

Taysha Gene Therapies (TSHA) beyond its filings: 3 active clinical trials.

Taysha Gene Therapies' latest quarter

Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Taysha Gene Therapies have?

3 active studies on ClinicalTrials.gov, 2 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.